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Abstract
TheY-boxbindingprotein-1(YB-1)isanoncogenictranscription/translation factorthatisactivated byphosphorylation atS102
whereby it induces the expression of growth promoting genes such as EGFR and HER-2. We recently illustrated by an in vitro
kinase assay that a novel peptide to YB-1 was highly phosphorylated by the serine/threonine p90 S6 kinases RSK-1 and RSK-2,
and to a lesser degree PKCa and AKT. Herein, we sought to develop this decoy cell permeable peptide (CPP) as a cancer
therapeutic. This 9-mer was designed as an interference peptide that would prevent endogenous YB-1
S102 phosphorylation
based on molecular docking. In cancer cells, the CPP blocked P-YB-1
S102 and down-regulated both HER-2 and EGFR transcript
level and protein expression. Further, the CPP prevented YB-1 from binding to the EGFR promoter in a gel shift assay. Notably,
the growth of breast (SUM149, MDA-MB-453, AU565) and prostate (PC3, LNCap) cancer cells was inhibited by ,90% with the
CPP. Further, treatment with this peptide enhanced sensitivity and overcame resistance to trastuzumab in cells expressing
amplified HER-2. By contrast, the CPP had no inhibitory effect on the growth of normal immortalized breast epithelial
(184htert) cells, primary breast epithelial cells, nor did it inhibit differentiation of hematopoietic progenitors. These data
collectively suggest that the CPP is a novel approach to suppressing the growth of cancer cells while sparing normal cells and
thereby establishes a proof-of-concept that blocking YB-1 activation is a new course of cancer therapeutics.
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Introduction
Cancer is a leading cause of death worldwide, with the World
Health Organization estimating 7.9 million deaths annually in
2007. The major cause of mortality in these patients can be
attributed to cancers that are resistant to current therapies either
intrinsically or through acquired mechanisms. In the case of breast
cancer, ,207,000 new cases will be diagnosed annually in the US
and Canada and ,46,000 women will die from this disease [1,2].
There are 5 subtypes of breast cancer and the mortality rates differ
depending on the subtype, with the triple-negative and HER-2
positive subtypes having the poorest prognoses [3]. The triple-
negative subtype, for example, does not respond to conventional
anti-hormone or molecular targeting therapies (i.e. trastuzumab)
and therefore has limited treatment options. Similarly, in the
HER-2 positive subtype, only 30–50% of patients respond to
trastuzumab and even then, these patients often develop resistance
over time [4,5]. For prostate cancer, an estimated 211,000 men
will be diagnosed with prostate cancer this year in North America
and 33,000 men will die from the disease [1,2]. Like breast cancer,
traditional hormone therapies are not effective in androgen-
independent prostate cancer and resistance to current therapies is
also common [6–8]. As a result, these subtypes of breast and
prostate cancer represent a significant unmet medical need.
Y-box binding protein-1 (YB-1) is a transcription and transla-
tion factor that alters the expression of at least ten genes strongly
linked to drug resistance and tumour cell growth such as the
epidermal growth factor receptor (EGFR) and the human
epidermal growth factor receptor-2 (HER-2). YB-1 has multiple
effects on cancer cells [9], with over-expression leading to
increased proliferation and siRNA silencing inhibiting growth
and inducing apoptosis. YB-1 has been shown to be highly
expressed in many cancers, including breast [10,11], prostate [12],
bone [13], lung [14,15], and colon [16]. YB-1 is also over-
expressed in a large proportion of brain tumours affecting adults
and children [17,18] whereby it underpins drug resistance to
classically administered drugs such as temozolamide [18]. We
have demonstrated that this protein was a strong predictive factor
for poor overall survival in breast cancer patients [11] and
recently, another group has shown that YB-1 is a predictive
marker of prognosis in non-small cell lung cancer [19]. Further,
YB-1 is preferentially expressed in cancers over normal adult
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12661Figure 1. Schematic of the YB-1 peptide inhibitor mode-of-action. A. We designed a molecular decoy peptide of 9 amino acids (shown in
red) that flanked the S102 site (shown in blue) on YB-1. The alignment of the peptide to the endogenous protein is shown. B. The YB-1 cell
permeable peptide was designed to function in the following way. In cancer cells receptor tyrosine kinases initiate signaling events that culminate in
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cancer therapeutics.
Previous work in our lab showed that the serine/threonine kinase
AKT phosphorylates, and thereby activates, YB-1 at S102 and that
inhibiting this site disrupts nuclear trafficking [20], DNA binding
[10] and tumour cell growth [20]. More recently, we determined
that p90 ribosomal S6 kinase (RSK) is the predominate kinase that
phosphorylates YB-1 at S102, and that PKCa and AKT do so to a
lesser degree [21]. Although relatively little is known about the
specific role that RSK plays in cancer, it has been reported to be
over-expressed in breast and prostate cancers, and has an important
role in the MAPK pathway, cell survival, and proliferation [21–24].
We therefore designed a YB-1 cell permeable peptide (CPP) to
compete for phosphorylation at S102 by RSK. Since this peptide
mimics the crucial activation site of YB-1, it should also block
endogenous phosphorylation of YB-1 by AKT and PKCa. Thus, in
theory, increasing concentrations of the interference peptide will
decrease the phosphorylation of wild-type YB-1 and prevent it from
binding to growth promoting/resistance genes. This approach
possesses several advantages: 1) Signal transduction inhibitors as
molecular targeting therapies for cancer have been clinically
validated with compounds such as trastuzumab (HerceptinH),
imatinib mesylate (GleevecH) and gefitinib (IressaH), 2) CPPs have
the potential to provide therapeutic options for triple-negative and
trastuzumab-resistant breast cancer as well as prostate cancer, and,
3) Since the YB-1 pathway has been implicated in many different
cancer types, the technology has broad utility.
We report here that the CPP was readily taken up by breast
cancer cells, inhibited phosphorylation of YB-1, and reduced
growth in a dose-dependant manner in models of incurable breast
cancer (triple-negative and HER-2+). These results correlated with
demonstrated suppression of EGFR and HER-2 protein and
transcript levels that are two YB-1 target genes. We found similar
results in androgen-independent (PC3) and dependent (LNCap)
prostate cancer cell lines. Further, the peptide had little effect on
the growth of normal breast epithelial cells or hematopoietic
progenitors. We therefore establish a proof-of-principle that
blocking P-YB-1
S102 is a potential axis for cancer therapeutics.
Materials and Methods
Cell permeable peptide development
The cell permeable peptide (CPP) was developed from the YB-1
peptide sequence containing the S102 site, PRKYLRSVG, and was
linked to antennapedia, a 16mer amino acid sequence (RQI-
KIWFQNRRMKWKK) that facilitates peptide delivery into cells
[25–27]. The control peptide, RALKYGVRP, was a scrambled
sequence of the CPP and was also linked to antennapedia (referred
to as scrambled peptide henceforth). Initially, these peptides were
biotin labeled and visualized with Oregon Green 514 (Gibco/
Invitrogen, Burlington, ON) to show that they entered the cell.
Once determined, further experiments were performed without the
biotin label. The peptides were custom synthesized by thinkpeptide
(ProImmune, Oxford, UK) and dissolved in 3% acetic acid to a
stock concentration of 25 mM.
Modeling phosphorylation of YB-1 by RSK
A model of the RSK-CPP-binding complex was built on a known
binding complex of AKT-GSK3b (PDB id 1o6k) [28], using the
Molsoft ICM 3.5-1m homology modeling and docking packages
[29]. We chose not to use existing RSK crystal structures, as they
possessed a 12-residue gap of a loop structure near the peptide-
binding site. First a homology model of RSK was built using AKT
as a reference (46% sequence identity over the kinase domain and
67% within residues 3.5 A ˚ to the peptide-binding site). The CPP
was then docked into the peptide-binding site of RSK, defined as a
box 3.5 A ˚ around the known GSK3b peptide-binding site. With the
supposition that the CPP would be phosphorylated at the serine site
(S102 in the complete YB-1 protein [20]), we visually scanned
through the list of docked conformations and selected those with the
serine residue in a position allowing for phosphorylation. These
conformations served as starting positions for further docking, each
time selecting a peptide with similar or better ICM docking score
and a superior binding conformation by backbone alignment to the
known GSK3b peptide conformation. The process concluded when
the binding poses and energies of the selected peptide conformation
stabilized over 5 iterations.
Cell culture
All cell lines were obtained from the American Tissue Culture
Collection (Manassus, VA) unless otherwise stated. Human
mammary epithelial cells (184htert, gift from Dr. J. Carl Barrett,
National Institutes of Health, Bethesda, MD) and the breast
cancer cell lines SUM149 (Asterand, Ann Arbor, MI), AU565,
BT474, BT474-m1 (a metastatic variant of BT474, gift from Dr.
Mien-Chi Hung, MD Anderson Cancer Center, Houston, TX),
the phosphorylation of YB-1
S102 by RSK, PKCa and/or AKT. Once YB-1 is activated, it promotes the expression of growth receptors such as EGFR or
HER-2. The CPP was therefore designed to enter cancer cells and serve as a sink for signaling via RSK, PKCa and AKT, since all of these kinases are
potentially capable of phosphorylating YB-1. This CPP mimics the S102 site and thereby accepts the phosphate from adjacent ATP-binding site on the
kinase, preventing endogenous YB-1 from becoming activated. In turn, growth-promoting genes are not transcribed, resulting in growth
suppression. C. We predict that the S102 site of YB-1 lies in a flexible loop region of the cold-shock domain of YB-1. This region would be able to bind
in a lock and key configuration to the peptide-binding site of the kinase domain of RSK, PKCa or AKT (shown). We hypothesize that this interaction
promotes a conformational change in YB-1 that allows it to bind DNA and act as a transcription factor. The CPP would therefore, in theory, inhibit
endogenous binding of YB-1. D. GSK3b, a known substrate of RSK, was used to further model how the CPP could align into the peptide-binding
pocket of RSK, the predominate kinase that phosphorylates YB-1. GSK3b is shown in light grey with the CPP in blue overlaid on top in a peptide-
binding pocket of RSK. The alignment was made manually so that the arginine (R) and serine (S) overlapped and would be in exact same
conformation. The R and S of GSK3b are shown in green while the R and S of CPP are purple. ATP is shown in orange to demonstrate the relative
positioning of the ATP-binding site. E. The CPP theoretically forms 16 H-bonds, shown as purple dashed lines, to the peptide-binding pocket of RSK.
The serine site (arrow) is in a position to allow for a hydrogen bond with RSK as well as receive a phosphate group from ATP.
doi:10.1371/journal.pone.0012661.g001
Table 1. Theoretical H-bonds formed by the interaction
between RSK and the CPP.
YB-1 CPP RSK
P1 Q351
R2 E342, E279 (3), Y316
K3 Q351, K353, G352, E315
R6 Q160, AMP-PNP
S7 AMP-PNP (2)
V8 G312 (2)
doi:10.1371/journal.pone.0012661.t001
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12661Figure 2. The CPP decreased YB-1 phosphorylation. A. To demonstrate the CPP entered cells, SUM149 cells were treated with either biotin-
labeled scrambled CPP (1.25 mM, left panel) or CPP (1.25 mM, right panel) for 1 h and then visualized by detecting the biotin tag (green color). The
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The HR5 and HR6’s are trastuzumab resistant cell lines [34]
obtained from Dr. Carlos Arteaga (Vanderbilt-Ingram Cancer
Center, Nashville, TN). Prostate cancer PC3 and LNCap cells
were grown in RPMI-1640 plus 10% FBS (Gibco/Invitrogen). All
cells were grown at 37uC with 5% CO2.
Oregon Green staining
SUM149 cells were plated at 3000 cells/well in a 96 well plate
and treated with DMSO, 1.25 mM biotin-labeled scrambled
peptide (Biotin-RQIKIWFQNRRMKWKKRALKYGVRP -
OH) or 1.25 mM CPP (Biotin-RRQIKIWFQNRRMKWKKPR-
KYLRSVG-OH) for 1 h at 37uC. The media was removed and
cells were fixed for 20 min in 2% paraformaldehyde/PBS, washed
with PBS and permeabilized with 0.1% Triton-X 100 for 10 min.
Cells were then incubated with 1/5000 dilution of Oregon Green
514 (Invitrogen) for 1 h, washed with PBS and stained with
0.5 mg/mL Hoechst (Sigma Chemical, Oakville, ON) for 3 min.
The ability of the peptides to enter the cell was analyzed on an
Arrayscan VTI Reader (Cellomics, Pittsburgh, PA).
Immunoblotting
Cell lines used herein were evaluated for YB-1, the activating
kinases RSK and AKT, and the downstream targets EGFR and
HER-2. To demonstrate that phophorylation of YB-1 was
decreased with CPP treatment, cells were treated with either
50 mM scrambled CPP or 12.5–50 mM of the CPP for 72 h.
Proteins were extracted using ELB plus protease and phosphatase
inhibitors and western blotting was performed as previously
described [10]. The following antibodies were used to detect
proteins by immunoblotting (unless otherwise indicated, all
antibodies were from Cell Signaling Technology, Danvers, MA):
P-YB-1
S102 (1/500), YB-1 (1/2000, Abcam, Cambridge, MA),
EGFR (1/5000, Stressgen, San Diego, CA), P-p90RSK
S380 (1/
500), RSK1/RSK2/RSK3 (1/1000), HER-2 (1/1000, Abcam),
AKT (1/1000), creb (1/1000), pan-actin (1/1000), vinculin (1/
1000). Blots were quantified using ImageJ software.
Real-time quantitative reverse transcription PCR
RNA was isolated from log growing AU565 and SUM149 cells
treated with 50 mM scrambled CPP or 50 mM CPP for 24 h using
the RNeasy Mini kit from Qiagen (Mississauga, ON). The RNA
was reverse transcribed and amplified using HER-2 (for AU565
cells) or EGFR (for SUM149 and AU565 cells) specific primers
and probes (Applied Biosystems, Foster City, CA). 18S mRNA was
quantified as a housekeeping gene (Applied Biosystems).
Electrophoretic mobility shift assay (EMSA)
The gel shift assay was performed using EGFR2a oligonucle-
otides as previously described [31]. Briefly, SUM149 cells were
harvested and cytoplasmic/nuclear fractions were obtained using
the NE-PER kit followed by EMSA using the Lightshift
Chemiluminescent EMSA kit (both kits from Pierce Biotechnol-
ogy, Rockford, IL). Nuclear extracts were confirmed to contain
RSK and YB-1 by immunoblotting. Nuclear protein (5 mg) was
pre-incubated for 20 min with unlabeled oligonucleotide plus
acetic acid control, scrambled peptide (25 mM), or CPP (25 mMo r
50 mM) prior to the addition of biotin-labeled oligonucleotide.
Chicken anti-YB-1 (1 mg) was used as positive control. Reactions
were run on a non-denaturing polyacrylamide gel, transferred to a
nylon membrane, cross-linked at 120 mJ/cm
2 using a Stratalinker
(Stratagene, La Jolla, CA) and visualized with chemiluminescence
(Pierce Biotechnology).
Growth assay
For monolayer assays, cells were plated at 5000 cells per well in a
96 well plate. The following day cells were treated with diluent, 0–
50 mM of scrambled peptide, or 0–50 mM CPP. The BT474,
BT474-m1, HR5 and HR6 cells were also tested in combination
with trastuzumab (BC Cancer Agency pharmacy, Vancouver, BC)
at 20 mg/mL. After 72 h treatment, cell growth was analyzed by
MTS for all cell lines except the AU565 cells. In the case of these
cells, MTS did not provide an accurate measurement of growth and
therefore the AU565 cells were stained with Hoechst and counted
on the Arrayscan VTI Reader (Cellomics) as previously described
[32]. Growth was shown as a percentage of diluent control and
changes in growth were considered significant at P,0.01.
Normal mammary epithelial cells assay
EpCAM
+ primary normal human breast epithelial cells from
two patients were obtained, prepared, and isolated as previously
described [35,36]. In all subsequent experiments, the primary
epithelial cells were grown in Epicult-B media (StemCell
Technologies, Vancouver, BC) supplemented with 5% fetal calf
serum. For the colony-forming cell (CFC) assay, EpCAM
+ cells
from each patient were first seeded at 7000 cells/well into a 96
well plate and treated the following day with either diluent,
scrambled peptide (6 or 25 mM), or CPP (6 or 25 mM) in triplicate
wells for 48 hours. Following this peptide incubation, cells were
harvested with trypsin, a single cell suspension was generated, and
cells were seeded into the CFC assay as previously described
[36,37]. Colonies were counted 7 days post-seeding. EpCAM
+
cells from each patient were also plated into a 96 well plate (1000
cells/well), treated the following day for 72 h with the same
peptide treatments as above, and analyzed for growth using an
MTS assay.
Hematopoietic progenitor assay
Thawed normal bone marrow cells were enriched for CD34+
cells using an immunomagnetic positive selection method (Easy-
Sep, StemCell Technologies) according to the manufacturer’s
instructions (CD34+ purity =94%). To measure the toxicity of the
YB-1 inhibitor peptide on the colony-forming cell hematopoietic
progenitors, CFC assays were set up with varying concentrations
of CPP (0–50 mM). The negative scrambled peptide and solvent
control were also included in the experiment. Aliquots of the cells
were plated in Methocult H4435 (StemCell Technologies) that
contains erythropoietin, steel factor, interleukin-3, interleukin-6,
granulocyte colony stimulating factor and granulocyte macro-
phage colony stimulating factor. Erythroid colonies (BFU-Es),
granulopoietic colonies (CFU-GMs) and multi-lineage colonies
(CFU-GEMM) were scored by direct visualization using an
inverted microscope (326) 14 days later using standard criteria
[38]. These values were then added together to obtain total CFC
counts per cells plated and expressed as % of control (the 0 mM
YB-1 assay).
nucleus was stained with Hoechst and is shown in blue. B. The CPP decreased P-YB-1
S102 by 32% in as little as 1 h in SUM149 cells. C–E. Further, the
CPP decreased phosphorylation of YB-1
S102 following 72 h treatment in SUM149, AU565, and LNCap cells, respectively. Blots were quantified using
ImageJ software and relative P-YB-1:YB-1 is shown below the western blots.
doi:10.1371/journal.pone.0012661.g002
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12661Figure 3. The CPP impaired YB-1s transcriptional activity against HER-2 and EGFR. A. Treating AU565 cells with the CPP for 72 h reduced
P-YB-1
S102 and that correlated with down-regulation of its target gene products EGFR and HER-2. B. HER-2 and EGFR transcripts are also markedly
decreased in AU565 cells after 24 h CPP treatment based on qRT-PCR. * P,0.01. C. Likewise, the CPP decreased P-YB-1
S102 and thus EGFR in SUM149
cells after 72 h. D. EGFR transcript levels were also decreased in the SUM149 cells following 24 h peptide treatment. * P,0.01. E. Nuclear extracts
were prepared from SUM149 cells. A western blot confirmed that the nuclear fraction (NF) contained the components (YB-1 and RSK) necessary for
the gel shift analysis. CF= cytoplasmic fraction. F. Nuclear proteins from breast cancer cells, SUM149, bind to the EGFR promoter DNA (lane 2)
compared to the unbound biotin labeled oligonucleotide DNA (lane 1). Binding was specific because cold competitive oligonucleotides to the same
sequence diminished binding (lane 3). The transcription factor responsible for binding was YB-1 because introducing 1 mg of YB-1 antibody (lanes 4)
caused a super-shift in the binding product. YB-1 bound with high affinity in the presence of acetic acid control (lane 5) and 25 mM scrambled
peptide (lane 6), whereas incubation with 25 mM of the CPP blocked binding and cause a super-shift (lane 7).
doi:10.1371/journal.pone.0012661.g003
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The transcription/translation factor YB-1 controls the expres-
sion of many growth regulatory and chemotherapy resistance
genes and is thus an attractive target for cancer therapies. We
designed a novel cell permeable peptide to competitively block
phosphorylation of YB-1 at S102 (Figure 1). This 9-mer (Figure 1A)
was tagged with an antennapedia leader sequence to facilitate
cellular uptake and was initially biotin labeled for detection. Our
objective was to produce an interference strategy whereby the CPP
would serve as a molecular decoy to accept phosphorylation by
kinases known to activate YB-1 at S102 such as RSK, PKCa and
AKT [21]. Our working model was that the CPP would prevent
phosphorylation of YB-1 and thereby block eventual transcrip-
tional activation of key growth promoting genes such as EGFR or
HER-2 (Figure 1B). This interference strategy should culminate in
cancer cell growth suppression. Based on the crystal structure of
the YB-1 cold-shock domain, we predicted that the S102 site
would be located in a flexible loop region (Figure 1C) and that this
area would fit into the peptide domains of RSK, PKCa or AKT in
a lock and key configuration that would be disrupted via the
interference peptide. Subsequently, YB-1 would be unable to bind
to DNA (Figure 1C).
To build upon this concept we used computational modeling to
show that the YB-1 peptide tethers to RSK. We chose to use RSK
for the model because we previously published that YB-1 was
efficiently phosphorylated by RSK1 and RSK2 [21]. A homology
model of RSK was used to show how the peptide binds in a
peptide-bound conformation and we used molecular docking to
theoretically define the binding of the CPP to RSK. The peptide-
binding site was adjacent to the ATP-binding pocket, with the
CPP serine residue in a position to accept a phosphate group
(Figure 1D). A space-filling model confirmed the CPP three-
dimensional fit into the peptide-binding pocket of RSK, adjacent
to this ATP-binding site (not shown). This RSK-YB-1 interaction
was stabilized by 16 hydrogen bonds throughout the length of the
peptide (Figure 1E, purple dotted lines; Table 1). For example, the
R2 side chain of the CPP formed 5 hydrogen bonds with RSK
(E342, E279 (3), Y316) and these were conserved in the solved
AKT-GSK3b complex (reference complex not shown). Further,
the peptide (catalytic) serine was in a position where it could form
a hydrogen bond to the protein as well as receive a phosphate
group from ATP (Figure 1E, arrow, indicated as S7). The ICM
docking score of the RSK-YB-1 complex was -55, which indicated
a high likelihood of a true binding interaction and was comparable
to the score calculated for known AKT-GSK3b binding. This
model therefore supports our previous work demonstrating that
RSK phosphorylates YB-1 at S102 [21] and confirmed that the
CPP could mimic this critical site. Thus, the competitive peptide
should prevent the flexible loop region of endogenous YB-1 from
binding to RSK.
The CPP and scrambled control peptides were made cell
permeable by fusing them to an antennapedia homeodomain
sequence demonstrated to cross biological membranes [25–27].
Initially, they were biotin labeled to show that the scrambled
control CPP and target CPP peptides rapidly entered SUM149
breast cancer cells to a similar degree within 1 hour where Oregon
Green immunofluorescence was used to detect the peptides
(Figure 2A). Once we determined that the CPP entered the cell,
we next evaluated changes in signal transduction and determined
that activation of YB-1
S102 was blocked in as little as one hour in
SUM149 cells (Figure 2B). Incubating cancer cells with increasing
concentrations of the CPP for 72 h depressed P-YB-1
S102 in
SUM149, AU565 and LNCap cells, respectively (Figure 2C-E).
Given this result, we next addressed whether blocking YB-1
activation with the CPP would impact the expression of its target
genes HER-2 or EGFR. After 72 h, the CPP reduced HER-2 and
EGFR protein levels in AU565 cells (Figure 3A). To further
support this observation, we used quantitative real-time PCR to
examine HER-2 and EGFR transcript levels and found that 24 h
treatment with the CPP resulted in a ,50% reduction of both
(Figure 3B). Further, in SUM149 cells, EGFR protein and mRNA
levels were decreased (Figure 3C-D). HER-2 was not detected
because the SUM149 cells do not express this protein, likely due to
differences in chromatin folding (Figure S1). We then extracted
nuclear proteins from SUM149 cells to address whether the CPP
interfered with YB-1’s ability to bind to the EGFR promoter using
gel shift assays. Prior to performing the gel shift, we determined
that RSK was indeed present in the nuclear fraction and
furthermore that it was activated based on S380 phosphorylation
(Figure 3E). As expected, YB-1 was also abundantly found in the
nuclear fraction (Figure 3E). The nuclear extracts containing
endogenous RSK and YB-1 were incubated with 25 mM CPP and
a gel shift assay was performed against the EGFR promoter in a
region that we previously reported contains a key inverted CAAT
region [10]. Nuclear proteins from SUM149 breast cancer cells
bind to the EGFR promoter DNA compared to the unbound
biotin labeled oligonucleotide DNA (Figure 3F, lane 1 vs. 2).
Diminished binding was seen with cold competitive oligonucleo-
tides, demonstrating that binding was specific (Figure 3F, lane 3).
The addition of a YB-1 (1 mg) antibody caused a super-shift in the
binding product, confirming that binding was due to this
transcription factor (Figure 3F, lane 4). To show that the CPP
could also cause a shift, nuclear extracts from SUM149 cells were
pre-incubated with the solvent control, scrambled peptide, or the
CPP. YB-1 bound with high affinity in the presence of diluent or
scrambled peptide (Figure 3F, lanes 5 and 6) whereas incubation
with 25 mM of the CPP blocked binding (Figure 3F, lane 7). These
results were independently confirmed with 25 mM and 50 mMo f
the CPP in a gel shift using SUM149 nuclear extracts (data not
shown). Taken together, these data show that the CPP successfully
blocked the activation of YB-1 and thereby prevented its binding
to the EGFR promoter. Further, this result supports our previous
work showing that YB-1 binds to EGFR in a S102 dependent
manner [10] and that the MAPK inhibitor PD098059 or the RSK
inhibitor SL0101 reverse YB-1 binding to the EGFR promoter
[21].
We nextquestioned whether the CPP would preferentially inhibit
tumour cell growth while sparing normal cells. The scrambled CPP
had no effect on growth (Figure 4A) while, consistent with an
Figure 4. The cell permeable peptide inhibited growth of breast and prostate cancer cell lines. A. The scrambled CPP had no effect on
the growth of breast cancer SUM149 cells following exposure for 72 h. B. The CPP inhibited the growth of breast (SUM149, MDA-MB-453 and AU565)
and prostate cancer cells (PC3 and LNCap) cell lines in a dose dependent manner after 72 h. *P,0.01 compared to control lane. Each of the cell lines
was tested with the peptides in replicates of three on two separate occasions. C. The CPP also suppressed the growth of BT474 and its metastatic
variant the BT474-m1 cells. Notably it increased the sensitivity of these cells to trastuzumab (20 mg/ml) following 72 h treatment. Further, treating the
trastuzumab resistant variants HR5 and HR6 with the CPP allowed the cells to overcome drug insensitivity. In all cell lines, the combination of CPP and
trastuzumab significantly (P,0.01) decreased growth compared to the control lane. Indicated (*) combinations were also significant (P,0.01)
compared to trastuzumab treatment alone.
doi:10.1371/journal.pone.0012661.g004
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dependent manner of breast (SUM149, MDA-MB-453, AU565)
and prostate (PC3, LNCap) cancer cell lines (Figure 4B). In most
cases, growth inhibition was .90% at the highest dose of 50 mM.
We next determined that the addition of the CPP sensitized the
HER-2 over-expressing cells BT474 and BT474-m1’s (a metastatic
variant of the former) to trastuzumab (HerceptinH) (Figure 4C). The
cells were treated for 72 h with trastuzumab (20 mg/ml), the CPP
(12.5 or 50 mM) or a combination of the two. Additionally, we
challenged the trastuzumab resistant variants HR5 and HR6 [34]
Figure 5. The CPP had no growth effect on normal breast epithelial cells or hematopoietic progenitors. A. Neither the scrambled CPP
nor the CPP affected the growth of normal immortalized human epithelial 184htert cells after being exposed to the peptide for 72 h based on MTS
proliferation assays. B. Normal breast epithelial cells were taken from two women (coded as 28-05 and 67-05) who had undergone a reduction
mammoplasty. The cells were isolated and treated with either the scrambled peptide or CPP (6 or 25 mM) for 72 h and then assessed for viability
using an MTS assay. These patients were also evaluated using the same amount of the peptides in a 7-day CFC output assay. C. Relative output of
hematopoietic progenitors remained unchanged with CPP treatment. CFC assays of CD34+ bone marrow cells were performed with various
concentrations of scrambled CPP or CPP. Erythroid colonies (BFU-Es), granulopoietic colonies (CFU-GMs) and multi-lineage colonies (CFU-GEMM)
were scored by direct visualization using an inverted microscope (326) after 14 days using standard criteria. These values were then added together
to obtain total CFC counts per cells plated and expressed as percent of control.
doi:10.1371/journal.pone.0012661.g005
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suppress growth in theseotherwise recalcitrant cell lines (Figure 4C).
By contrast, neither the scrambled control peptide nor the CPP
inhibited growth of normal human mammary epithelial cells
(184htert) (Figure 5A). The lack of activity in the 184htert cells
suggest that the peptide does not have unwarranted off-target effects
given the observation that these cells do not express YB-1 [30]
(Figure S1). This result suggested that the growth inhibitory effect of
the CPP in cancer cells depends upon the expression of YB-1. It has
previously been shown that YB-1 is undetectable in normal breast
tissue [39] or in normal bone marrow plasma cells [40]. To further
determine the potential safety of this peptide, we report that neither
the scrambled peptide nor the CPP had any growth effect on
normal breast epithelial cells taken from reduction mammoplasties
based on MTS as well as CFC assays (Figure 5B). Secondly, in a
hematopoietic progenitor assay, differentiation of normal blood
progenitor cells was not altered by the CPP (Figure 5C). Taken
together, these assays illustrate that the CPP caused a growth
inhibition in cancer cells but not in normal cells.
Cancer cells are generally thought to have hijacked normal
control mechanisms that regulate proliferation and survival. RSK
itself has been shown to be an important regulator of proliferation
[23,24] and our data supports the hypothesis that blocking RSK
with the CPP causes growth suppression. In recent years, directly
targeting cell-signaling pathways to inhibit cancer growth has
gained momentum, with the development of rationally designed
peptide inhibitors, monoclonal antibodies and small molecules.
Interference peptides that target oncogenic pathways, such as the
CPP described herein, may have broad utility in cancer
therapeutics, or, at the very least, substantiate promising
therapeutic targets. Examples such as shepherdin, a peptidomi-
metic that blocks the interaction of survivin and Hsp90, causing
massive apoptosis in cancer cells, highlights the feasibility of such
an approach [27,41]. This anti-cancer agent is remarkably
selective with high affinity to cancer cells, well tolerated in vivo,
and non-toxic to normal cells. Shepherdin is also more potent than
other Hsp90 inhibitors, validating this more targeted approach.
The on-going development of other cell penetrating peptide
inhibitors against factors such as NF-kB [42] and c-Myc [43],
among others, demonstrates that these directed therapies comprise
an active area of research [44,45]. Further, efforts to stabilize
peptides through chemical modifications such as peptide stapling
promises to expand the repertoire of achievable therapies [46].
Our work with the CPP suggests that the YB-1 axis is also a
promising target for cancer therapeutics and we are actively
pursuing this lead.
Supporting Information
Figure S1 Cell line western blots. A. Normal immortalized
mammary epithelial cells (184htert cells) do not express YB-1
although they do have RSK and AKT. A and B. The cancer cells
lines used herein express YB-1, P-YB-1 and the activating kinases
RSK and AKT.
Found at: doi:10.1371/journal.pone.0012661.s001 (0.65 MB TIF)
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